- Home
- LENZ
as of 12-15-2025 10:29am EST
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | SOLANA BEACH |
| Market Cap: | 852.0M | IPO Year: | 2021 |
| Target Price: | $56.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $15.70 - $50.40 | Next Earning Date: | 11-05-2025 |
| Revenue: | $17,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 204.72% |
AI-Powered LENZ Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of LENZ Therapeutics Inc. (LENZ)
Chief Commercial Officer
Avg Cost/Share
$26.05
Shares
10,000
Total Value
$261,022.18
Owned After
4,733
Director
Avg Cost/Share
$22.79
Shares
10,500
Total Value
$239,278.20
Owned After
10,500
SEC Form 4
10% Owner
Avg Cost/Share
$46.26
Shares
224,974
Total Value
$10,352,017.45
Owned After
821,752
10% Owner
Avg Cost/Share
$42.63
Shares
135,304
Total Value
$5,714,356.00
Owned After
821,752
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Olsson Shawn | LENZ | Chief Commercial Officer | Nov 17, 2025 | Sell | $26.05 | 10,000 | $261,022.18 | 4,733 | |
| MCCOLLUM JAMES W | LENZ | Director | Nov 7, 2025 | Buy | $22.79 | 10,500 | $239,278.20 | 10,500 | |
| Versant Venture Capital VI, L.P. | LENZ | 10% Owner | Sep 30, 2025 | Sell | $46.26 | 224,974 | $10,352,017.45 | 821,752 | |
| Versant Venture Capital VI, L.P. | LENZ | 10% Owner | Sep 18, 2025 | Sell | $42.63 | 135,304 | $5,714,356.00 | 821,752 |
Compare LENZ vs Leading Stocks
See how LENZ stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LENZ LENZ Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.